Pharmacokinetic Study of HR17031 Injection in Healthy Subjects (Single-center, Randomized, Open-label, 4 Cycles, 4 Sequences)
Latest Information Update: 17 Oct 2022
Price :
$35 *
At a glance
- Drugs HR 17031 (Primary) ; HS 20004 (Primary) ; Insulin degludec (Primary)
- Indications Obesity; Type 1 diabetes mellitus; Type 2 diabetes mellitus
- Focus Pharmacokinetics
- Sponsors Jiangsu Hengrui Medicine Co.
- 12 Oct 2022 Status changed from active, no longer recruiting to completed.
- 22 Sep 2021 Status changed from not yet recruiting to active, no longer recruiting.
- 08 Sep 2021 New trial record